Targeting Disease at the Nuclear Pore
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.

Our Commitment to Patients

SINE Technology

Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis.

Scientist doctor looking at sample in test tube

Pipeline

Our drug pipeline includes 4 unique investigational medicines targeting both hematologic malignancies and solid tumors.

Press Releases

April 1, 2020
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 17, 2020
Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Recent Medical Conferences

Conference: American Society of Hematology (ASH) Annual Meeting
Location: Orlando, FL, USA
Date: December 7 – 10

Targeting Disease at the Nuclear PoreKaryopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.